Previous 10 | Next 10 |
PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cog...
Cognition Therapeutics press release (NASDAQ:CGTX): Q1 GAAP EPS of $0.17 beats by $0.46. Cash and cash equivalents of $51.51M For further details see: Cognition Therapeutics GAAP EPS of $0.17 beats by $0.46
Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease Data Presented at Scientific Conferences Further Validate the Potential of σ-2 Modulators PURCHASE, N.Y., May 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeu...
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of the release, the report date should be Wednesday, May 11, 2022, not Tuesday as previously sta...
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “...
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) , a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina, presented a poster today at the ann...
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) , a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster a...
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that members of its management team...
PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that the company would be participa...
Gainers: Protalix BioTherapeutics (PLX) +74%. Aterian (ATER) +62%. Dingdong Limited (DDL) +40%. Jumia Technologies (JMIA) +30%. Twitter (TWTR) +27%. Takung Art (TKAT) +24%. Gracell Biotechnologies (GRCL) +22%. Cognition Therapeutics (CGTX) +21%. Poema Global Holdings (PPGH) +20%. Biophytis (B...
News, Short Squeeze, Breakout and More Instantly...
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
Cognition Therapeutics Inc. Website:
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024...
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical e...
Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease (AD); topline results expected 2Q 2023 SHINE (AD) trial currently enrolling patients with first patient in Spain enrolled. Expect full enrollment by end of 2023 Received FDA clearance to...